贝复新应用于糜烂性湿疹治疗的疗效观察及对患者症状体征评分的影响

The efficacy of Beifuxin in the treatment of erosive eczema and its influence on the symptom scores

目的观察贝复新应用于糜烂性湿疹治疗的疗效及对患者症状体征评分的影响。方法选择2018年1月至2018年10月于本院皮肤科就诊的200例糜烂性湿疹患者,按照随机数字表法将其分成两组,每组100例。对照组患者采用曲安奈德益康唑乳膏治疗,观察组在对照组的治疗基础上加用贝复新治疗。连续治疗2周,比较两组患者治疗后临床疗效,治疗前后症状体征评分变化,同时比较两组患者创面治愈时间、自觉症状以及治疗期间不良反应发生情况。结果治疗2周后,观察组患者临床总有效率(90.0%)明显高于对照组患者(70.0%),差异有统计学意义(P<0.05);两组患者症状体征评分均较治疗前降低,其中观察组症状体征评分明显低于对照组,差异具有统计学意义(P<0.05);观察组患者创面治愈时间明显较对照组短,治疗后3~4d自觉症状减轻患者数量明显多于对照组,不良反应发生率(0.0%)明显低于对照组(8.0%);差异均具有统计学意义(P<0.05)。结论贝复新能有效改善糜烂性湿疹患者皮疹、瘙痒等临床症状,缩短患者治愈时间,临床疗效显著,安全性较高。

Objective To observe the curative effect of Beifuxin in the treatment of erosive eczema and its influence on symptom and sign score of patients. Methods 200 patients with erosive eczema from January 2018 to October 2018 in dermatology department of our hospital were selected and they were divided into two groups according to random number table method, with 100 cases in each group. The patients in the control group were treated with triamcinolone acetonide and Econazole cream, while the patients in the observation group were treated with befuxine on the basis of the treatment in the control group. After 2 weeks of continuous treatment, the clinical efficacy of the two groups were compared, and the changes of symptoms and signs scores before and after treatment were compared. At the same time, the healing time of wounds, conscious symptoms and adverse reactions during treatment were compared between the two groups. Results After 2 weeks of treatment, the total clinical effective rate (90.0%) of patients in the observation group was significantly higher than that of patients in the control group (70.0%), and the difference was statistically significant (P<0.05);the scores of symptoms and signs in both groups were lower than before treatment. The scores of symptoms and signs in the observation group were significantly lower than those in the control group (P<0.05);the healing time of wounds in the observation group was shorter than that in the control group, and the number of patients with conscious symptoms alleviated 3-4 days after treatment was significantly more than that in the control group, and the incidence of adverse reactions (0.0%) was significantly lower than that in the control group (8.0%);the difference was statistically significant (P<0.05). Conclusion Befloxacin can effectively improve the clinical symptoms of erosive eczema such as rash and pruritus, shorten the healing time of patients, have significant clinical efficacy and high safety.